RuthA.KarronMD

Pediatric Infectious Disease • Baltimore, MD

Joint of Pediatrics, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Karron is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karron's full profile

Already have an account?

Office
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone+1 410-614-3917

Education & Training

Johns Hopkins UniversityFellowship, Infectious Disease, 1987 - 1988
National Capital ConsortiumResidency, Pediatrics, 1985 - 1987
Children's National HospitalResidency, Pediatrics, 1982 - 1985
New York University School of MedicineClass of 1982

Certifications & Licensure

MD State Medical License 1989 - 2026
American Board of Pediatrics Pediatrics

Clinical Trials

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A) Start of enrollment: 2005 Jun 01
Completed
Phase 1
Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants Start of enrollment: 2006 Jun 01
Completed
Phase 1
Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults Start of enrollment: 2006 Jun 01
Completed
Phase 1
Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults Start of enrollment: 2007 Mar 01
Completed
Phase 1
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B) Start of enrollment: 2006 Oct 01
Completed
Phase 1
Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults Start of enrollment: 2007 Jun 01
Completed
Phase 1
Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine Start of enrollment: 2008 Mar 01
Completed
Phase 1
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children Start of enrollment: 2009 Nov 01
Completed
Phase 1
Safety Study of a Human Metapneumovirus Challenge Virus in Healthy Adults Start of enrollment: 2010 Jun 01
Completed
Phase 1
Safety of a Live Attenuated Human Parainfluenza Virus Type 2 (HPIV2) Vaccine for Adults, Children, and Infants Start of enrollment: 2010 Jun 01
Completed
Phase 1
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine Start of enrollment: 2011 Jan 01
Completed
Phase 1
Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children Start of enrollment: 2011 Aug 01
Completed
Phase 1
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Start of enrollment: 2013 Oct 01
Completed
Phase 1
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children Start of enrollment: 2013 Jun 01
Active, not recruiting
Phase 1
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Start of enrollment: 2014 Sep 01
Completed
Phase 1
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age Start of enrollment: 2016 Sep 01
Terminated
Phase 1
Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age Start of enrollment: 2016 Aug 01
Completed
Phase 1
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age Start of enrollment: 2017 Apr 01
Completed
Phase 1
Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children Start of enrollment: 2017 Oct 13
Completed
Phase 1
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age Start of enrollment: 2017 Oct 04
Active, not recruiting
Phase 1
Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children Start of enrollment: 2018 Jun 25
Recruiting
Phase 1
Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age Start of enrollment: 2019 May 16
Completed
Phase 1, Phase 2
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age Start of enrollment: 2022 Feb 23
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Understanding Kenyan policymakers' perspectives about the introduction of new maternal vaccines.
Rupali J Limaye, Berhaun Fesshaye, Prachi Singh, Rose Jalang'o, Rosemary Njura Njogu
Health Policy and Planning. 2025-01-11
key antecedents and questions for acceptance of a future maternal GBS vaccine: Perspectives of pregnant women, lactating women, and community members in Kenya.
Rupali J Limaye, Prachi Singh, Berhaun Fesshaye, Clarice Lee, Jessica Schue
Human Vaccines & Immunotherapeutics. 2024-12-31
Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected Children.
Matthew S Kelly, Coleen K Cunningham, Elizabeth J McFarland, Mark J Giganti, Jane C Lindsey
Open Forum Infectious Diseases. 2024-12-01

Journal Articles

Informing Randomized Clinical Trials of Respiratory Syncytial Virus Vaccination During Pregnancy to Prevent Recurrent Childhood Wheezing: A Sample Size Analysis
Tina V Hartert, Niranjan Bhat, Ruth A Karron, Justin R Ortiz, ScienceDirect

Authored Content

An ‘Indefensible’ Decision: Not Vaccinating Pregnant and Lactating Women in an Ebola OutbreakAugust 2018

Press Mentions

We’ll Soon Have Tools To Protect Infants Against RSV. Can We Put Them To Good Use?May 24th, 2023
FDA Approves First Vaccine for RSV, a Moment Six Decades in the MakingMay 3rd, 2023
FDA Approves World’s First RSV Vaccine for Adults 60 and OlderMay 3rd, 2023
Join now to see all

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/ruth-karron